Date: 2015-06-08
Type of information: Nomination
Compound:
Company: Alnylam Therapeutics (USA - MA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 8, 2015, Alnylam Pharmaceuticals, a leading RNAi therapeutics company, announced the appointment of David-Alexandre \"DA\" Gros, M.D. to the position of Senior Vice President, Chief Business Officer. Dr. Gros joins Alnylam with extensive experience in the pharmaceutical industry and in healthcare investment banking and consulting. At Alnylam, he will be responsible for the company\'s corporate and business development, finance, corporate communications, and investor relations functions. In addition, Dr. Gros will be joining the Alnylam Management Board. Most recently, Dr. Gros was Executive Vice President and Chief Strategy Officer at Sanofi, where he was a member of the Executive Committee and the Global Leadership Team. His responsibilities included leading corporate strategy, business development and licensing, mergers and acquisitions, alliance management, and structured investments including the corporate venture fund. During his tenure, he oversaw the execution of over 100 successful transactions and the launch of Sanofi\'s corporate venture activities, and he was closely involved in the company\'s key alliances with Alnylam and Regeneron. Prior to Sanofi, he held management positions with a focus on the pharmaceutical industry in investment banking at Centerview Partners and Merrill Lynch & Co, and in consulting at McKinsey & Co. Dr. Gros holds an M.D. from The Johns Hopkins University School of Medicine , an M.B.A. from Harvard Business School , and a B.A. from Dartmouth College .
Financial terms:
Latest news:
